Primary Prevention of Hypertension in Obese Adolescents
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00288158|
Recruitment Status : Completed
First Posted : February 7, 2006
Last Update Posted : September 14, 2017
The purpose of this study is to examine the consequences of lowering serum uric acid in pre-hypertensive, obese adolescents pathways involved with how uric acid mediated hypertension and renal disease. The specific aims are:
- Test the hypothesis that lowering uric acid will improve endothelial function.
- Test the hypothesis that lowering uric acid will reduce plasma renin activity and serum angiotensin II levels.
- Test the hypothesis that lowering uric acid will reduce markers of inflammation
|Condition or disease||Intervention/treatment||Phase|
|Obesity Pre-Hypertension Hyperuricemia||Drug: Allopurinol Drug: Probenecid Drug: Placebo||Phase 2|
The trial will be a double blinded, placebo control trial of two uric acid lowering agents. The endpoints for this trial will be, endothelial function, systemic vascular resistance, plasma renin activity, MCP-1 and CRP. Upon recruitment and informed consent, children will undergo initial screening. This will include medical history, family history, dietary history, review of systems (questionnaire used and validated in pediatric hypertension clinic) and pediatric quality of life questionnaire. They will have a physical exam, casual and ambulatory blood pressure monitoring (see below) and screening laboratory analysis that will include CBC, electrolytes, BUN, Cr, Uric acid, AST, ALT and urinary micro-albumin to creatinine ratio. Children with serum uric acid less than 5.0mg per dl will be enrolled as controls and only have baseline studies at Screening and Visit 1. Children with serum uric acid equal to or greater than 5.0mg per dl will be randomized (in a one to one to one ratio) to receive placebo, allopurinol or probenecid.
Study drug (or placebo) will be administered for 2 months. During the first week, subjects will take one tablet (placebo, 150mg allopurinol or 250mg probenecid) twice daily. At the end of one week subjects will be instructed to increase to 2 tablets (placebo, 300mg allopurinol or 500mg probenecid) twice daily. Data collection will occur during screening, after one and two months on the study drug and one month after completion of the study drug.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Actual Study Start Date :||September 2008|
|Primary Completion Date :||January 2011|
|Study Completion Date :||January 2011|
|Experimental: Allopurinol||Drug: Allopurinol|
|Experimental: Probenecid||Drug: Probenecid|
|Active Comparator: Placebo||Drug: Placebo|
- Casual BP [ Time Frame: 3 months ]
- 24- hour Ambulatory BP [ Time Frame: 3 months ]
- Systemic Vascular Resistance (measured by bioimpedance) [ Time Frame: 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00288158
|United States, Texas|
|Texas Children's Hospital|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Daniel I Feig, MD, PhD||Baylor College of Medicine|